SCHEMBL8018089

SCHEMBL8018089

Cc1ccc2oc(C(N)=O)cc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.55
TAS1R1 Q7RTX1 3/20 0.55
MAOB P27338 7/20 0.54
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29994212 1.00 TAS1R3 (0.55) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL11684788 0.85 ALDH1A1 (0.69) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL702631 0.85 PIM1 (0.64) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL4504897 0.84 TAS1R3 (0.54) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL8034219 0.82 TAS1R3 (0.59) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL6238132 0.82 TAS1R3 (0.68) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL23665730 0.81 TAS1R3 (0.58) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL1065473 0.81 TAS1R3 (0.55) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL16708233 0.80 TAS1R3 (0.53) TAS1R3TAS1R1MAOBCA12CA1
SCHEMBL10508628 0.79 FLT3 (0.76) MAOBCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3131893-B1 POLYCYCLIC HERG ACTIVATORS NOVARTIS AG (CH) 2020-02-12 EP disclosed
EP-3131893-B1 POLYCYCLIC HERG ACTIVATORS NOVARTIS AG (CH) 2020-02-12 EP disclosed
CN-106604918-B Polycyclic hERG activators 诺华股份有限公司 2019-09-27 CN disclosed
CN-106604918-A Polycyclic hERG activators 诺华股份有限公司 2017-04-26 CN disclosed
EP-3131893-A1 POLYCYCLIC HERG ACTIVATORS Novartis AG (CH) 2017-02-22 EP disclosed
US-20160108025-A1 POLYCYCLIC HERG ACTIVATORS NOVARTIS AG 2016-04-21 US disclosed
US-20160108025-A1 POLYCYCLIC HERG ACTIVATORS NOVARTIS AG 2016-04-21 US disclosed
US-20160108025-A1 POLYCYCLIC HERG ACTIVATORS NOVARTIS AG 2016-04-21 US disclosed
US-9255093-B2 Polycyclic HERG activators NOVARTIS AG (CH) 2016-02-09 US disclosed
US-9255093-B2 Polycyclic HERG activators NOVARTIS AG (CH) 2016-02-09 US disclosed
EP-1497279-B1 SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS MERCK PATENT GMBH (DE) 2011-03-09 EP disclosed
US-7888470-B2 Chimeric T1R taste receptor polypeptides and nucleic acid sequences encoding and cell lines that express said chimeric T1R polypeptides SENOMYX, INC. (US) 2011-02-15 US disclosed
US-20090291963-A1 SUBSTITUTED INDOLES SCHADT OLIVER 2009-11-26 US disclosed
US-20090291963-A1 SUBSTITUTED INDOLES SCHADT OLIVER 2009-11-26 US disclosed
US-7572796-B2 Substituted indoles MERCK PATENT GMBH (DE) 2009-08-11 US disclosed
US-7572796-B2 Substituted indoles MERCK PATENT GMBH (DE) 2009-08-11 US disclosed
WO-2009094279-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK & CO., INC. (US) 2009-07-30 WO disclosed
US-20090054459-A1 Substituted indoles SCHADT OLIVER 2009-02-26 US disclosed
US-20090054459-A1 Substituted indoles SCHADT OLIVER 2009-02-26 US disclosed
US-20080085994-A1 Chimeric binding protein for use in identifying compounds which respond to umami taste stimuli and sweet taste stimuli SENOMYX, INC. 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054459-A1 Substituted indoles TPH2, TPH1, HTR1A TAS1R3 3775/4885TAS1R1 3074/4885MAOB 52/4885
US-20090291963-A1 SUBSTITUTED INDOLES TPH2, TPH1, HTR1A TAS1R3 3802/4885TAS1R1 3125/4885MAOB 45/4885
US-20160108025-A1 POLYCYCLIC HERG ACTIVATORS KCNH3, KCNH2, KCNJ11 TAS1R3 2106/4885TAS1R1 2047/4885MAOB 2514/4885
US-20080085994-A1 Chimeric binding protein for use in identifying compounds which respond to umami taste stimuli and sweet taste stimuli TAS1R3, TAS1R2, TAS2R30 TAS1R3 1/4885TAS1R1 4/4885MAOB 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.